JP2019501191A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019501191A5 JP2019501191A5 JP2018535283A JP2018535283A JP2019501191A5 JP 2019501191 A5 JP2019501191 A5 JP 2019501191A5 JP 2018535283 A JP2018535283 A JP 2018535283A JP 2018535283 A JP2018535283 A JP 2018535283A JP 2019501191 A5 JP2019501191 A5 JP 2019501191A5
- Authority
- JP
- Japan
- Prior art keywords
- lyophilized formulation
- present
- amount
- total weight
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012931 lyophilized formulation Substances 0.000 claims description 64
- 239000000203 mixture Substances 0.000 claims description 23
- 229940125904 compound 1 Drugs 0.000 claims description 22
- 238000009472 formulation Methods 0.000 claims description 21
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 16
- 239000004067 bulking agent Substances 0.000 claims description 14
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims description 12
- 239000013011 aqueous formulation Substances 0.000 claims description 10
- 229960004543 anhydrous citric acid Drugs 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 208000032839 leukemia Diseases 0.000 claims description 8
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 7
- 239000007979 citrate buffer Substances 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 4
- 229920000858 Cyclodextrin Polymers 0.000 claims description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 4
- 239000013543 active substance Substances 0.000 claims description 4
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 239000001116 FEMA 4028 Substances 0.000 claims description 2
- 108010002386 Interleukin-3 Proteins 0.000 claims description 2
- 102100039064 Interleukin-3 Human genes 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 2
- 229960004853 betadex Drugs 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 claims description 2
- 229940111134 coxibs Drugs 0.000 claims description 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims description 2
- 239000002955 immunomodulating agent Substances 0.000 claims description 2
- 229940121354 immunomodulator Drugs 0.000 claims description 2
- 230000002584 immunomodulator Effects 0.000 claims description 2
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 2
- 230000001861 immunosuppressant effect Effects 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 229960001855 mannitol Drugs 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000000651 prodrug Substances 0.000 claims description 2
- 229940002612 prodrug Drugs 0.000 claims description 2
- 230000000306 recurrent effect Effects 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 239000012453 solvate Substances 0.000 claims description 2
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- WQNHWIYLCRZRLR-UHFFFAOYSA-N 2-(3-hydroxy-2,5-dioxooxolan-3-yl)acetic acid Chemical compound OC(=O)CC1(O)CC(=O)OC1=O WQNHWIYLCRZRLR-UHFFFAOYSA-N 0.000 claims 5
- ZMIBIIAWFMCVFD-UHFFFAOYSA-N 2,2-difluoroacetamide Chemical compound NC(=O)C(F)F ZMIBIIAWFMCVFD-UHFFFAOYSA-N 0.000 claims 2
- -1 hydroxypropyl Chemical group 0.000 claims 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 2
- PWBHUSLMHZLGRN-UHFFFAOYSA-N 2-(4-chlorophenyl)-N-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]methyl]-2,2-difluoroacetamide Chemical compound ClC1=CC=C(C=C1)C(C(=O)NCC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)(F)F PWBHUSLMHZLGRN-UHFFFAOYSA-N 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000003319 supportive effect Effects 0.000 claims 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000009120 supportive therapy Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021068923A JP7201732B2 (ja) | 2016-01-08 | 2021-04-15 | ２－（４－クロロフェニル）－ｎ－（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－５－イル）メチル）－２，２－ジフルオロアセトアミドの製剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662276756P | 2016-01-08 | 2016-01-08 | |
| US62/276,756 | 2016-01-08 | ||
| PCT/US2017/012483 WO2017120437A1 (en) | 2016-01-08 | 2017-01-06 | Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021068923A Division JP7201732B2 (ja) | 2016-01-08 | 2021-04-15 | ２－（４－クロロフェニル）－ｎ－（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－５－イル）メチル）－２，２－ジフルオロアセトアミドの製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019501191A JP2019501191A (ja) | 2019-01-17 |
| JP2019501191A5 true JP2019501191A5 (enExample) | 2020-06-25 |
| JP6871256B2 JP6871256B2 (ja) | 2021-05-12 |
Family
ID=59273934
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018535283A Active JP6871256B2 (ja) | 2016-01-08 | 2017-01-06 | ２−（４−クロロフェニル）−ｎ−（（２−（２，６−ジオキソピペリジン−３−イル）−１−オキソイソインドリン−５−イル）メチル）−２，２−ジフルオロアセトアミドの製剤 |
| JP2021068923A Active JP7201732B2 (ja) | 2016-01-08 | 2021-04-15 | ２－（４－クロロフェニル）－ｎ－（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－５－イル）メチル）－２，２－ジフルオロアセトアミドの製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021068923A Active JP7201732B2 (ja) | 2016-01-08 | 2021-04-15 | ２－（４－クロロフェニル）－ｎ－（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－５－イル）メチル）－２，２－ジフルオロアセトアミドの製剤 |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US10052315B2 (enExample) |
| EP (2) | EP3399979B9 (enExample) |
| JP (2) | JP6871256B2 (enExample) |
| KR (1) | KR20180100565A (enExample) |
| CN (2) | CN108601777B (enExample) |
| AU (2) | AU2017205167B2 (enExample) |
| BR (1) | BR112018013884A2 (enExample) |
| CA (1) | CA3010797C (enExample) |
| CL (1) | CL2018001830A1 (enExample) |
| CO (1) | CO2018008305A2 (enExample) |
| EA (1) | EA037508B1 (enExample) |
| EC (1) | ECSP18051143A (enExample) |
| ES (1) | ES2956767T3 (enExample) |
| IL (1) | IL260403B (enExample) |
| MX (1) | MX382150B (enExample) |
| SA (1) | SA518391983B1 (enExample) |
| SG (2) | SG10202007913WA (enExample) |
| WO (1) | WO2017120437A1 (enExample) |
| ZA (1) | ZA201804482B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9499514B2 (en) | 2014-07-11 | 2016-11-22 | Celgene Corporation | Antiproliferative compounds and methods of use thereof |
| EP3399979B9 (en) | 2016-01-08 | 2023-10-04 | Celgene Corporation | Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
| AU2017205170B2 (en) * | 2016-01-08 | 2021-06-24 | Celgene Corporation | Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies |
| EA201892746A1 (ru) | 2016-06-06 | 2019-06-28 | Селджин Корпорейшн | Лечение гематологической злокачественной опухоли с помощью 2-(4-хлорфенил)-n-((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-5-ил)метил)-2,2-дифторацетамида |
| US20190030018A1 (en) | 2017-06-30 | 2019-01-31 | Celgene Corporation | Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
| WO2020142422A1 (en) * | 2018-12-31 | 2020-07-09 | Celgene Corporation | Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5yl) methyl)-2,2-difluoroacetamide |
| US12090147B2 (en) | 2019-11-05 | 2024-09-17 | Celgene Corporation | Combination therapy with 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
| AU2020396543A1 (en) | 2019-12-06 | 2022-06-16 | Celgene Corporation | Processes for preparing 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
| MX2023008296A (es) | 2021-01-13 | 2023-09-29 | Monte Rosa Therapeutics Inc | Compuestos de isoindolinona. |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5391485A (en) | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
| JPS63500636A (ja) | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ |
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US5360352A (en) | 1992-12-24 | 1994-11-01 | The Whitaker Corporation | Wire retainer for current mode coupler |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5948893A (en) | 1996-01-17 | 1999-09-07 | The United States Of America As Represented By The Secretary Of The Navy | Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody |
| US6207157B1 (en) | 1996-04-23 | 2001-03-27 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate vaccine for nontypeable Haemophilus influenzae |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| DK1212422T3 (da) | 1999-08-24 | 2007-07-02 | Medarex Inc | Humane CTLA-4-antistoffer og anvendelserne deraf |
| CA2466279A1 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| US7498171B2 (en) | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
| CA2508660C (en) | 2002-12-23 | 2013-08-20 | Wyeth | Antibodies against pd-1 and uses therefor |
| KR101498834B1 (ko) | 2005-05-09 | 2015-03-05 | 오노 야꾸힝 고교 가부시키가이샤 | 예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법 |
| HRP20080053A2 (hr) | 2005-07-01 | 2009-08-31 | Medarex | Ljudska monoklonska protutijela na ligand 1 za programiranu smrt stanice (pd-l1) |
| US8877780B2 (en) | 2006-08-30 | 2014-11-04 | Celgene Corporation | 5-substituted isoindoline compounds |
| CN100457098C (zh) * | 2006-12-20 | 2009-02-04 | 南京科源医药技术有限公司 | 甲磺酸萘莫司他冻干粉针剂及其制备方法 |
| CN104945508B (zh) | 2007-06-18 | 2019-02-22 | 默沙东有限责任公司 | 针对人程序性死亡受体pd-1的抗体 |
| CN101224296A (zh) * | 2008-02-01 | 2008-07-23 | 山东先声麦得津生物制药有限公司 | 一种稳定的重组人血管内皮抑制素制剂及其制备工艺 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| EP3133086B1 (en) | 2008-09-26 | 2018-08-01 | Dana-Farber Cancer Institute, Inc. | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses thereof |
| CA2741299C (en) * | 2008-10-29 | 2017-03-28 | Celgene Corporation | Isoindoline compounds for use in the treatment of cancer |
| CA3120172A1 (en) | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| US8741295B2 (en) | 2009-02-09 | 2014-06-03 | Universite De La Mediterranee | PD-1 antibodies and PD-L1 antibodies and uses thereof |
| US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
| US20130022629A1 (en) | 2010-01-04 | 2013-01-24 | Sharpe Arlene H | Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof |
| WO2011159877A2 (en) | 2010-06-18 | 2011-12-22 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| AU2012236655B2 (en) * | 2011-03-28 | 2016-09-22 | Deuterx, Llc, | 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds |
| US8974811B2 (en) * | 2013-03-14 | 2015-03-10 | Hikma Pharmaceuticals | Stabilized pharmaceutical formulations comprising antineoplastic compounds |
| TW201534305A (zh) | 2013-05-03 | 2015-09-16 | Celgene Corp | 使用組合療法治療癌症之方法 |
| US9499514B2 (en) | 2014-07-11 | 2016-11-22 | Celgene Corporation | Antiproliferative compounds and methods of use thereof |
| HRP20201789T1 (hr) | 2016-01-08 | 2021-01-22 | Celgene Corporation | Antiproliferativni spojevi, te njihovi farmaceutski pripravci i uporabe |
| EP3399979B9 (en) * | 2016-01-08 | 2023-10-04 | Celgene Corporation | Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
| ES2959267T3 (es) | 2016-01-08 | 2024-02-22 | Celgene Corp | Formas sólidas de 2-(4-clorofenil)-n-((2-2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida y sus composiciones farmacéuticas y usos |
| JP2019011495A (ja) | 2017-06-30 | 2019-01-24 | 株式会社Ｕａｃｊ押出加工 | 熱交換器に配管部材を接続するためのアルミニウム合金製コネクタ及び該コネクタを備える熱交換器接続用配管部材、並びにこれらの製造方法 |
| WO2020142422A1 (en) | 2018-12-31 | 2020-07-09 | Celgene Corporation | Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5yl) methyl)-2,2-difluoroacetamide |
| US12090147B2 (en) | 2019-11-05 | 2024-09-17 | Celgene Corporation | Combination therapy with 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
-
2017
- 2017-01-06 EP EP17736406.4A patent/EP3399979B9/en active Active
- 2017-01-06 US US15/400,791 patent/US10052315B2/en active Active
- 2017-01-06 CA CA3010797A patent/CA3010797C/en active Active
- 2017-01-06 BR BR112018013884A patent/BR112018013884A2/pt not_active Application Discontinuation
- 2017-01-06 EA EA201891578A patent/EA037508B1/ru unknown
- 2017-01-06 WO PCT/US2017/012483 patent/WO2017120437A1/en not_active Ceased
- 2017-01-06 MX MX2018008429A patent/MX382150B/es unknown
- 2017-01-06 SG SG10202007913WA patent/SG10202007913WA/en unknown
- 2017-01-06 CN CN201780005873.3A patent/CN108601777B/zh active Active
- 2017-01-06 KR KR1020187019190A patent/KR20180100565A/ko not_active Ceased
- 2017-01-06 CN CN202110818391.8A patent/CN113633634A/zh active Pending
- 2017-01-06 AU AU2017205167A patent/AU2017205167B2/en active Active
- 2017-01-06 ES ES17736406T patent/ES2956767T3/es active Active
- 2017-01-06 SG SG11201805777QA patent/SG11201805777QA/en unknown
- 2017-01-06 JP JP2018535283A patent/JP6871256B2/ja active Active
- 2017-01-06 EP EP23181094.6A patent/EP4275707A3/en not_active Withdrawn
-
2018
- 2018-07-03 IL IL260403A patent/IL260403B/en unknown
- 2018-07-04 CL CL2018001830A patent/CL2018001830A1/es unknown
- 2018-07-04 ZA ZA201804482A patent/ZA201804482B/en unknown
- 2018-07-05 SA SA518391983A patent/SA518391983B1/ar unknown
- 2018-07-06 EC ECSENADI201851143A patent/ECSP18051143A/es unknown
- 2018-07-19 US US16/040,450 patent/US10449187B2/en active Active
- 2018-08-08 CO CONC2018/0008305A patent/CO2018008305A2/es unknown
-
2019
- 2019-09-09 US US16/565,346 patent/US11129821B2/en active Active
-
2021
- 2021-04-15 JP JP2021068923A patent/JP7201732B2/ja active Active
- 2021-08-25 US US17/412,187 patent/US11883389B2/en active Active
- 2021-09-29 AU AU2021240184A patent/AU2021240184A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019501191A5 (enExample) | ||
| JP2021113206A5 (enExample) | ||
| JP2019131596A5 (enExample) | ||
| HRP20230210T1 (hr) | Pripravci i postupci upotrebe 2-(4-klorofenil)-n-((2-(2,6-dioksopiperidin-3-il)-1-oksoizoindolin-5-il)metil)-2,2-difluoroacetamida | |
| ES2424476T3 (es) | Nanopartículas cargadas con fármaco antitumoral quimioterápico | |
| US20050085446A1 (en) | Fluoroquinolone formulations and methods of making and using the same | |
| JP7229999B2 (ja) | ダプトマイシン製剤 | |
| JP2019517587A5 (enExample) | ||
| JP6734971B2 (ja) | がん治療薬 | |
| JP2009530413A5 (enExample) | ||
| JP2013511557A5 (enExample) | ||
| JP2010530376A5 (enExample) | ||
| JP2013532729A5 (enExample) | ||
| JPWO2004028567A1 (ja) | 薬物吸収性改善剤 | |
| JP7597778B2 (ja) | シクロデキストリン及びブスルファンを含有する組成物 | |
| AU2003227702A1 (en) | Epothilone derivative for the treatment of hepatoma and other cancer diseases | |
| JP2019516765A5 (enExample) | ||
| CN113329734A (zh) | 新颖的药物制剂 | |
| JP6498610B2 (ja) | カバジタキセル組成物 | |
| FR3056108B1 (fr) | Utilisation des harringtonines dans le traitement cancer du sein, notamment triple-negatif | |
| JP7149991B2 (ja) | 発泡剤を含む抗微生物組成物 | |
| WO2019242688A1 (zh) | 3-羟基氨基苯甲酸与索拉非尼联合用药治疗肿瘤 | |
| WO2014131360A1 (zh) | 普罗布考及其衍生物抗肿瘤转移的用途 | |
| JP2020536126A (ja) | 経口ベンダムスチン製剤 | |
| CN114173761B (zh) | 包含乌地那非的药物组合物 |